🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07653321
Enrolling by invitation Observational

Acute Kidney Injury in Critically Ill Patients

NCT07653321 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Chao Yang Hospital
Phase
Observational
Started
2026-05-01
Last updated
2026-06-17

Condition(s) studied

Acute Kidney Injury

Investigational drug(s) / intervention(s)

Not applicable- observational study

Not applicable- observational study: Save the blood and urine samples

Study summary

Acute kidney injury (AKI) in critically ill patients is characterized by high incidence, delayed diagnosis and treatment, and high mortality. Early identification and precision management are key to improving prognosis. Currently, in China, the population with severe AKI faces prominent challenges, including a lack of standardized, localized specialized data, insufficient early warning and subtyping capabilities, and a shortage of high-quality evidence-based guidance for clinical decision-making. These issues constrain the application of artificial intelligence (AI) technologies in the precision diagnosis and treatment of AKI.

Leveraging the Critical Care Medicine Specialty Alliance, which has been approved by the Beijing Hospital Management Center and consists of 19 tertiary hospital ICUs nationwide, this project will conduct a three-year prospective, observational registry study. The investigators plan to consecutively enroll 23,600 adult critically ill patients (with an anticipated \>3,000 AKI patients). The study will systematically collect clinical characteristics, time-series monitoring data, laboratory parameters, renal ultrasound imaging, biomarkers, and omics data, while concurrently retaining biological samples, to establish the largest multi-modal specialized disease dataset and biobank for severe AKI in China.

Focusing on the entire AKI continuum of "early warning - diagnosis - phenotyping - treatment - prognosis," the study aims to: ① characterize the epidemiological features and disease burden of ICU-AKI in China; ② develop an early warning system for AKI; ③ identify AKI sub-phenotypes using machine learning and establish a precision management framework; ④ develop an intelligent decision support system for renal replacement therapy; ⑤ evaluate prognosis; and ⑥ promote medical-engineering collaborative translation. Expected outcomes include 3-5 early warning/prognostic models and one intelligent decision support system, along with applications for 3-5 invention patents and 2-3 software copyrights. The project aims to translate at least one outcome into practical application, provide high-level evidence-based support for developing national guidelines on severe AKI management tailored to China's context, and contribute to reducing the incidence and mortality of AKI.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years; 2. Expected ICU stay ≥ 24 hours; 3. Informed consent signed. Exclusion Criteria: 1. End-stage renal disease (ESRD) on maintenance dialysis; 2. Post-renal transplant; 3. Pregnant women; 4. Lactating women; 5. Advanced cancer; 6. End-stage disease; 7. AKI already diagnosed prior to ICU admission; 8. Expected survival \< 48 hours; 9. Refusal to participate in the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Chao Yang Hospital Beijing China

More Beijing Chao Yang Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07653321 on ClinicalTrials.gov ↗ ← All trials in China